Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


2 06, 2012

ASCO UPDATE: Kyprolis, pomalidomide and MLN9708

Tags: , , , , , , |2 Comments

  As I mentioned in my post from earlier today, it was another quiet day for myeloma related news here at ASCO. But there were clinical study results released for the "big three" of pending experimental myeloma therapies:  Carfilzomib (trade name: Kyprolis), pomalidomide and MLN9708. Nothing earth shattering here.  But no unexpected hiccups, either. Let's

30 05, 2012

Why isn’t ASCO’s PR machine working overtime this week?

Tags: , , , , , , , , |0 Comments

I need to be honest with you.  I am underwhelmed by multiple myeloma related news coming out of Chicago this week ahead of the American Society of Oncology (ASCO) meetings Friday. Most years my inbox would be flooded with press releases, touting when and where results from any number of different myeloma related studies can

25 05, 2012

A reader shares his step by step decision to undergo a stem cell transplant (Part Two)

Tags: , , , |6 Comments

Yesterday in Part One of my post, patient reader (and now contributor) Bill O'Halloran shared the first steps in his decision making process about whether to undergo an autologous stem cell transplant--or possibly two. Let's resume Bill's analytical journey as he examines the pros and cons of transplanting now or later: Autologous Stem Cell Transplant

25 01, 2012

Helpful summary of new proteasome inhibitor anti-myeloma agents in the research pipeline

Tags: , , , , |0 Comments

Here is a link to an excellent Myeloma Beacon review/summary which compares different experimental proteasome inhibitors Marizomib (NPI-0052) and MLN9708 with Velcade and carfilzomib: Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011) Hopefully, each of these three new agents will help a number of patients who have become refractory to Velcade

31 12, 2011

Millennium Pharmaceutical’s year in review

Tags: , , , , |0 Comments

I wanted to share some excerpts from a sort of "year in review" interview with Dr. Deborah Dunsire, CEO of Millennium Pharmaceuticals, makers of Velcade.  I found this article on a site called Mass High earlier this month: Millennium reports myeloma drug advances, updates drug recalls By Lori Valigra, Mass High Tech correspondent Cambridge: 

29 12, 2011

Dr. Paul Richardson reviews encouraging trial results from ASH

Tags: , , , , , , |2 Comments

Medscape Today has released an excellent written and video review of multiple myeloma-related news from ASH. Dr. Paul Richardson, well known myeloma specialist with Dana-Farber in Boston, kicks things off by reviewing results from several exciting new, experimental drugs that his research group are studying. MLN9708, an oral proteasome inhibitor, and marizomib, a particularly potent

18 04, 2011

Every Multiple Myeloma Patient Or Caregiver Should Read Friday’s Myeloma Beacon Feature About Emerging Myeloma Therapies

Tags: , , , , , , , , |2 Comments

The Myeloma Beacon ran an excellent review of new anti-myeloma therapies which are in late stages of development:  Promising New Drugs For Myeloma: Will The Future Come Soon Enough?The article is written by Dr. S. Vincent Rajkumar with Mayo Clinic.  I was going to reference it over the weekend, but forgot about it until I

25 05, 2010

Clarification About New Oral Proteasome Inhibitor–MLN9708 From Millennium

Tags: , , , , , |6 Comments

Sunday, I ran a story about Millennium Pharmaceutical's upcoming research presentations at ASCO. At the end of the article, I commented about the lack of attention being paid to Millennium's development of an "oral Velcade," a new drug, MLN9708.For years, the myeloma community has heard rumors Millennium was close to unveiling such a drug.  Now, practically

23 05, 2010


Tags: , , , , , , |1 Comment

I learned yesterday VELCADE is being highlighted in five presentations at the newly established, exclusive Trials in Progress session. This session will highlight a number of different abstracts. “Data being presented at this year’s ASCO further demonstrate the effectiveness of VELCADE as a backbone of therapy in a range of multiple myeloma patient populations and

19 10, 2009

Are Myeloma Blogs Becoming Too Technical?

Tags: , , |3 Comments

Cancer blogs and Websites run the gambit from highly emotional personal stories to highly technical reviews of drug trials and scientific studies. Multiple myeloma sites are no different. After my initial diagnosis, I soon became frustrated by the lack of technical information available in books or on the Internet. That is why I wrote my

19 10, 2009

MLN-4924 & MLN-9708

Tags: , , |0 Comments

Here are two more drugs that are expected to "work better" or "be better" than Velcade. I first wrote about both of these last July. Both are going to be manufactured by the same company, Millennium, that makes Velcade. MLN-4924. A new drug in Phase I trials that has shown encouraging results in pre-clinical trials

24 07, 2009

Let’s Get Technical!

Tags: , , , |0 Comments

OK. Enough emotional stuff! Let's get to the exciting techno breakthrough stuff guaranteed to give myeloma patients a different type of hope; the scientific kind. MLN-4924. A new drug in Phase I trials that has shown encouraging results in pre-clinical trials against both hematologic and solid tumors. MLN-9708. Also in Phase I trials. Researchers at